{
    "clinical_study": {
        "@rank": "43659", 
        "acronym": "SSc-calcinosis", 
        "brief_summary": {
            "textblock": "This is a 3 year study of scleroderma patients with calcinosis 1) to better understand how\n      common and if there are any risk factors for having calcinosis\n\n      2) to identify common complications associated with scleroderma-related calcinosis.\n\n      ."
        }, 
        "brief_title": "Calcinosis in a Single-Center Scleroderma Population", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Scleroderma", 
            "Calcinosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Calcinosis", 
                "Scleroderma, Systemic", 
                "Scleroderma, Diffuse", 
                "Scleroderma, Localized"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective study of scleroderma- spectrum patients focused on soft tissue\n      calcinosis in order 1) to better understand the risk factors (including clinical/laboratory\n      characteristics, and serology) of calcinosis in the scleroderma-spectrum disorders (limited\n      or diffuse systemic sclerosis with or without overlap of inflammatory arthritis and/or\n      myositis).\n\n      2) view common complications associated with calcinosis.\n\n      Better understanding of scleroderma calcinosis would lead to other studies that eventually\n      will define better treatment options for this incurable and often disabling complication."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult scleroderma subjects with and without calcinosis\n\n        Exclusion Criteria:\n\n          -  Subjects unwilling to participate"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Adult scleroderma subjects with and without calcinosis will be enrolled"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02062125", 
            "org_study_id": "Pro2012001886"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "scleroderma", 
            "calcinosis"
        ], 
        "lastchanged_date": "February 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New Brunswick", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "08903"
                }, 
                "name": "RWJ Medical School"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Prospective, Observational Study of Calcinosis in a Single-Center Population With Scleroderma-Spectrum Disorders", 
        "overall_contact": {
            "email": "hsuvm@rwjms.rutgers.edu", 
            "last_name": "Vivien Hsu, MD", 
            "phone": "732-418-8484"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This is an observational study of scleroderma calcinosis over 3 years duration, to assess possible risk factors (including serologic studies and disease types) as well as common complications that occur in those with scleroderma calcinosis in this time period.\nNo additional intervention will be delivered, other than standard of care for this complication.", 
            "measure": "risk factors and outcomes in scleroderma calcinosis", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02062125"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rutgers, The State University of New Jersey", 
            "investigator_full_name": "Vivien Hsu, M.D.", 
            "investigator_title": "Associate Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Rutgers, The State University of New Jersey", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rutgers, The State University of New Jersey", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "3 Years", 
        "verification_date": "February 2014"
    }
}